Esketamine: Approved for MDD Monotherapy
Esketamine is first monotherapy for MDD with inadequate response to oral antidepressants, approved after a priority FDA review. Esketamine has been approved […]
Spravato Breakthrough Treatment
Spravato (esketamine therapy) is a promising treatment for those with treatment-resistant depression, offering rapid relief where traditional antidepressants may fail.
